| GLAUKOS CORP. DL-,001 |
| USA |
| Gesundheit |
| US3773221029 / A14VCK |
| 6GJ (Frankfurt) / GKOS (NYSE) |
| FRA:6GJ, ETR:6GJ, 6GJ:GR, NYSE:GKOS |
| - |
| https://www.glaukos.com/ |
|
Glaukos Corporation is a medical technology company dedicated to the development and commercialization of innovative products for the treatment of glaucoma, corneal disorders, and retinal diseases. Its primary function is to address the substantial u..
>Volltext.. |
| 5667.43 Mio. EUR |
| 5520.87 Mio. EUR |
| 439.6 Mio. EUR |
| -38.45 Mio. EUR |
| -162.6 Mio. EUR |
| -2.83 EUR |
| 92.3 Mio. EUR |
| 78.67 Mio. EUR |
| -12.81 Mio. EUR |
| 2.75 |
| 16.63% |
| -13.02% |
| - |
| - |
| - |
| GLAUKOS |
| 05.04.26 |
|